亚洲人成网线在线播放va蜜芽_粉嫩小仙女扒开双腿自慰_日韩成人无码片AV网站_久久亚洲日韩成人无码导航_国产日韩国欧美三区

返回首頁 在線留言 聯(lián)系我們

產(chǎn)品目錄

聯(lián)系方式

首頁 > 技術(shù)支持 > 液體活檢:外周血游離循環(huán)腫瘤細胞(CTC)保存管

技術(shù)支持

液體活檢:外周血游離循環(huán)腫瘤細胞(CTC)保存管
更新時間:2018-01-26   點擊次數(shù):4791次

腫瘤CTC介紹

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy,

Catherine Alix-Panabières,Cancer Discov;6(5); 479–91. ©2016 AACR Published OnlineFirst March 11, 2016; DOI: 10.1158/2159-8290.CD-15-1483.

 

原發(fā)腫瘤(乳房、結(jié)腸、肺、前列腺癌)在形成生長早期,會釋放細胞進入血液循環(huán)。通過各種技術(shù)可以富集檢測這些循環(huán)腫瘤細胞的物理和生物性質(zhì)。

循環(huán)腫瘤細胞,Circulating Tumor cell,簡稱CTC。CTC釋放點:原發(fā)腫瘤和轉(zhuǎn)移腫瘤。

CTC死亡后還會釋放出循環(huán)腫瘤DNA,Circulating Tumor DNA,簡稱ctDNA。

 

CTC和ctDNA的臨床應(yīng)用

腫瘤檢測 CTCs和ctDNA應(yīng)用腫瘤的早期檢測很受關(guān)注,面臨的挑戰(zhàn)是目前分析的特定性和敏感度。

預(yù)后評估 多種腫瘤已經(jīng)實現(xiàn)預(yù)后評估,尤其是乳癌。

指導(dǎo)系統(tǒng)治療

病人亞群分類(stratification)。

 

 

外周血游離循環(huán)腫瘤細胞(CTC)保存管

——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管內(nèi)含特殊保護劑,可以保護循環(huán)腫瘤細胞,常溫下可以保存CTC達7天。

英文名稱:Streck Cell-Free DNA BCT® BLOOD COLLECTION TUBE

中文名稱:Streck BCT® 血漿游離DNA采血/保存

貨號:218962,230253

 

Streck 血漿游離DNA采血管是一種直接提取的全血收集管,用于收集、運輸和儲存血液樣本。Streck 血漿游離DNA采血管內(nèi)含防腐劑,它能穩(wěn)定有核血細胞,防止細胞基因組DNA的釋放,保護血漿游離循環(huán)DNA和循環(huán)腫瘤細胞(CTC)。

230253是Streck Cell-Free DNA BCT® 10mL采血管218962的升級版,是Streck公司新推將玻璃和塑料的*性能融合在一起的Fusion2TM混合塑料管。

 

Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管應(yīng)用

NIPT無創(chuàng)產(chǎn)前檢測:孕婦外周血的胎兒游離DNA保存

腫瘤液體活檢:循環(huán)腫瘤細胞(CTCs)和ctDNA(循環(huán)腫瘤DNA)保存

其他:血漿基因組DNA和游離DNA保存

 

Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管基因保存性能

游離DNA、細胞內(nèi)基因組DNA和循環(huán)腫瘤細胞樣本保存/穩(wěn)定性

 

樣本類型

游離DNA

胞內(nèi)基因組DNA

腫瘤細胞(上皮細胞)

樣本保存時間

14天

14天

7天

樣本保存溫度

6-37℃

6-37℃

15-30℃

 

 

Streck 218962(現(xiàn)貨),230253 Cell-Free DNA BCT采血管歡迎您咨詢華雅再生醫(yī)學(xué)旗艦公司:紅榮微再(上海)生物工程技術(shù)有限公司  :1500 1904 520。紅榮微再-客服: 2395557778  經(jīng)銷商專員。

 

 

 

 

外周血游離循環(huán)腫瘤細胞(CTC)保存管

——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管

文獻使用Circulating Tumor Cells (CTCs)

Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival

Boffa D.J., Graf R.P., Salazar M.C., Hoag J., Lu D., Krupa R., et al.

Cancer Epidemiology, Biomarkers & Prevention, 2017.

Chromosomal instability estimation based on next generation sequencing and single cell genome wide copy number variation analysis

Greene S.B., Dago A.E., Leitz L.J., Wang Y., Lee J., Werner S.L., et al.

PLoS One, 2016.

Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples

Gogoi P., Sepehri S., Zhou Y., Gorin M.A., Paolillo C., Capoluongo E., et al.

PLoS One, 2016.

Detection and characterization of circulating tumour cells in multiple myeloma

Zhang L., Beasley S., Prigozhina N.L., Higgins R., Ikeda S., Lee F., et al.

Journal of Circulating Biomarkers, 2016.

Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer

Scher H.I., Lu D., Schreiber N.A., Louw J., Graf R., Vragas H.A., et al.

Journal of the American Medical Association Oncology, 2016.

A novel approach for next-generation sequencing of circulating tumor cells

Yee S.S., Lieberman D.B., Blanchard T., Rader J., Zhao J., Troxel, A.B., et al.

Molecular Genetics & Genomic Medicine, 2016.

Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumour cell detection and characterization

Werner S.L., Graf R.P., Landers M., Valenta D.T., Schroeder M., Greene S.B., et al.

Journal of Circulating Biomarkers, 2015.

Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction

Bethel K., Luttgen M.S., Damani S., Kolatkar A., Lamy R., Sabouri-Ghomi M., et al.

Physical Biology, 2014.

Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer

Chudziak J., Burt D.J., Mohan S., Rothwell D.G., Mesquita B., Antonello J., et al.

Analyst, 2015.

Detection and characterization of circulating tumour cells from frozen peripheral blood mononuclear cells

Lu D., Graf R.P., Harvey M., Madan R.A., Heery C., Marte J., et al.

Journal of Circulating Biomarkers, 2015.

Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients

Ruiz C., Li J., Luttgen M.S., Kolatkar A., Kendall J.T., Flores E., et al.

Physical Biology, 2015.

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

Punnoose E.A., Ferraldeschi R., Szafer-Glusman E., Tucker E.K., Mohan S., Flohr P., et al.

British Journal of Cancer, 2015.

Rapid changes in circulating tumor cells following anti-angiogenic therapy

Gross M.E., Dorff T.B., Quinn D.I., Agus D.B., Luttgen M., Bethel K., et al.

Convergent Science Physcial Oncology, 2015.

Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer

Carlsson A., Nair V.S., Luttgen M.S., Keu K.V., Horng G., Vasanawala M., et al.

Journal of Thoracic Oncology, 2014.

An observational study of circulating tumor cells and 18F-FDG PET uptake in patients with treatment-naïve non-small cell lung cancer

Nair V.S., Keu K.V., Luttgen M.S., Kolatkar A., Vasanawala M., Kuscher W., et al.

PLoS One, 2013.

Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient

Phillips K.G., Velasco C.R., Li J., Kolatkar A., Luttgen M., Bethel K., et al.

Frontiers in Oncology, 2012.

Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient

Phillips K.G., Kolatkar A., Rees K.J., Rigg R., Marrinucci D., Luttgen M., et al.

Frontiers in Oncology, 2012.

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/ inflammatory, and stage IV breast cancer, using a novel detection technology

Somlo G., Lau S.K., Frankel P., Hsieh H.B., Liu X., Yang L., et al. Breast Cancer Research and Treatment, 2011.

Cytomorphology of circulating colorectal tumor cells: a small case series

Marrinucci D., Bethel K., Lazar D., Fisher J., Huynh E., Clark P., et al.

Journal of Oncology, 2010.

Sensitive characterization of circulating tumor cells for improving therapy selection

Hsieh H.B., Somlo G., Bennis R., Frankel P., Krivacic R.T., Lau S., et al.

SBEC, 2010, IFMBE Proceedings 32.

外周血游離循環(huán)腫瘤細胞(CTC)保存管

——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管

 

 

 

訂購信息

 

品牌

貨號

產(chǎn)品描述

包裝

Streck

218962

Cell-Free DNA BCT® BLOOD COLLECTION TUBE

Cell-Free DNA BCT®血漿游離DNA采血管

100管/盒

Streck

230253

Cell-Free DNA BCT® BLOOD COLLECTION TUBE

Cell-Free DNA BCT®血漿游離DNA采血管(混合塑料)

100管/盒

 

外周血游離循環(huán)腫瘤細胞(CTC)保存管

Streck 218962(現(xiàn)貨),230253 Cell-Free DNA BCT采血管及更多液體活檢產(chǎn)品歡迎您咨詢華雅再生醫(yī)學(xué)旗艦公司:紅榮微再(上海)生物工程技術(shù)有限公司  :1500 1904 520。紅榮微再-客服: 2395557778  經(jīng)銷商專員。紅榮微再以“傳遞科學(xué)價值,服務(wù)科學(xué)研究”為宗旨主營干細胞、醫(yī)療、細胞治療、器官再生四大板塊的產(chǎn)品。

 

 

分享到:

返回列表 | 返回頂部
上一篇 : 液體活檢:血漿游離循環(huán)腫瘤DNA(ctDNA)Streck 保存管    下一篇 :  外周血游離核酸Streck Cell-free cfDNA保存管
網(wǎng)站首頁 公司簡介 產(chǎn)品中心 應(yīng)用案例 技術(shù)支持 企業(yè)動態(tài) 聯(lián)系我們
紅榮微再(上海)生物工程技術(shù)有限公司 版權(quán)所有 總訪問量:881279
地址:上海市閔行區(qū)顧戴路2337號維璟中心G幢19C2
GoogleSitemap 技術(shù)支持:化工儀器網(wǎng) ICP備案號:滬ICP備20015702號-1
手機:
15021010459
 

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站